Diabetes patients who were implanted with a second-generation everolimus-eluting stent showed lower stent thrombosis rates and all-cause mortality compared with those who had first-generation sirolimus-eluting and paclitaxel-eluting stents, a study indicated. The results appear in the Journal of the American College of Cardiology: Cardiovascular Interventions.
Everolimus-eluting stent curbs thrombosis, mortality risk in diabetes
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||